seekingalpha.com · 11 jul

Elevance Health: Defense For An Undervalued Price

Elevance Health has outperformed the benchmark, rising 28% versus 11%, and I see further upside potential. ELV demonstrates steady top- and bottom-line growth, supporting a premium multiple and reinforcing management confidence. The insurance market's steady growth is a structural tailwind; if ELV maintains market share, it stands to benefit.

zacks.com · 10 jul

Is ELV's Capital Allocation Strategy Creating Long-Term Value?

Elevance Health's disciplined capital allocation, strong cash generation and continued investments in Carelon and AI support long-term growth while rewarding shareholders.

zacks.com · 10 jul

Curious about Elevance Health (ELV) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

zacks.com · 9 jul

3 Cheap Medical Stocks to Buy as US-Iran Tensions Keep Markets on Edge

U.S.-Iran tensions likely to lift demand for defensive plays, with Tenet Healthcare, Elevance Health and Aveanna Healthcare standing out as cheap medical stocks.

zacks.com · 8 jul

Analysts Estimate Elevance Health (ELV) to Report a Decline in Earnings: What to Look Out for

Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

businesswire.com · 6 jul

Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-39.

zacks.com · 3 jul

Can Elevance Recover $115 Million Through Its CMS Lawsuit?

ELV seeks to recover an estimated $115 million through a CMS lawsuit over Medicare Advantage Star Ratings and disputed bonus payments.

zacks.com · 26 jun

Can Carelon Drive Elevance Health's Future Earnings Growth?

Carelon is becoming a major growth driver for ELV, boosting revenues, care efficiency and long-term earnings potential despite near-term investment pressure.